Haraldsdottir S, Li Q, Villalona-Calero MA, Olencki TE, Kendra K, Ing SWCase of Sorafenib-Induced Thyroid Storm.J Clin Oncol in press 4/22/2013
Wu C, Fernandez SA, Criswell T, Chidiac TA, Guttridge D, Villalona-Calero M, Bekaii-Saab TSDisrupting Cytokine Signaling in Pancreatic Cancer: A Phase I/II Study of Etanercept in Combination With Gemcitabine in Patients With Advanced Disease.Pancreas in press 3/4/2013
Duan W, Gao L, Zhao W, Leon M, Sadee W, Webb A, Resnick K, Wu X, Ramaswamy B, Cohn DE, Shapiro C, Andreassen PR, Otterson GA, Villalona-Calero MAAssessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.Transl Res 161(3) 156-64 3/1/2013
Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Saradhi UV, Liu Z, Schwind S, Mims A, Byrd JC, Grever MR, Villalona-Calero MA, Klisovic R, Walker A, Garzon R, Blum W, Chan KK, Marcucci GIn vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia.AAPS J 15(1) 242-9 1/1/2013
Bertino EM, Bekaii-Saab T, Fernandez S, Diasio RB, Karim NA, Otterson GA, Villalona-Calero MAA phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC).Lung Cancer 79(1) 27-32 1/1/2013
Chu BF, Karpenko MJ, Liu Z, Aimiuwu J, Villalona-Calero MA, Chan KK, Grever MR, Otterson GAPhase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer.Cancer Chemother Pharmacol 71(1) 115-21 1/1/2013
Chao BH, Briesewitz R, Villalona-Calero MARET fusion genes in non-small-cell lung cancer.J Clin Oncol 30(35) 4439-41 12/10/2012
Jänne PA, Wang X, Socinski MA, Crawford J, Stinchcombe TE, Gu L, Capelletti M, Edelman MJ, Villalona-Calero MA, Kratzke R, Vokes EE, Miller VARandomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.J Clin Oncol 30(17) 2063-9 6/10/2012
Lam ET, Goel S, Schaaf LJ, Cropp GF, Hannah AL, Zhou Y, McCracken B, Haley BI, Johnson RG, Mani S, Villalona-Calero MAPhase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors.Cancer Chemother Pharmacol 69(2) 523-31 2/1/2012
Peck J, Wei L, Zalupski M, O'Neil B, Villalona MA, Bekaii-Saab THER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib.Oncology 82(3) 175-9 1/1/2012
Zhao W, Huang CC, Otterson GA, Leon ME, Tang Y, Shilo K, Villalona MAAltered p16(INK4) and RB1 Expressions Are Associated with Poor Prognosis in Patients with Nonsmall Cell Lung Cancer.J Oncol 2012 957437 1/1/2012
Blum KA, Ruppert AS, Woyach JA, Jones JA, Andritsos L, Flynn JM, Rovin B, Villalona-Calero M, Ji J, Phelps M, Johnson AJ, Grever MR, Byrd JCRisk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.Leukemia 25(9) 1444-51 9/1/2011
Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MAMulti-institutional phase II study of selumetinib in patients with metastatic biliary cancers.J Clin Oncol 29(17) 2357-63 6/10/2011